AAPL Down 18% YTD as Apple's AI Delays Erode Investor Confidence
Apple Inc. (AAPL) has long been the most reliable name in tech. It offered predictable product cycles, loyal customers, and industry-defining design. Investors called it boring in the best possible way. That was before 2025.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
This year, AAPL is down nearly 19% while the rest of the so-called 'Magnificent Seven' soar. Microsoft (MSFT), Nvidia (NVDA), Meta Platforms (META), Alphabet (GOOG) (GOOGL), Amazon (AMZN), and Tesla (TSLA) have all bounced back sharply. The S&P 500 (SPY) and Nasdaq have pushed higher on AI tailwinds. AAPL is the only one lagging.
'Siri, Why Are You Lagging? '
The reason sits at the core of Apple's identity. Artificial intelligence was supposed to be the company's next leap. A redesigned Siri, powered by new large language models, would act as a smart assistant across apps, emails, and calendars. It was shown off last year under the banner of 'Apple Intelligence.' Ads aired. Expectations built. Then came the delays.
According to recent reports in The Financial Times and The Wall Street Journal, the upgrade is nowhere near ready. Internal demos fell flat. Engineers cited hundreds of bugs. Ads featuring The Last of Us star Bella Ramsey were quietly pulled. Executives have now postponed the launch indefinitely. One former Apple leader called the AI plan a stumble. Investors agree.
Sentiment Is Cooling
TipRanks data shows a cooling in analyst sentiment. There are fewer 'Strong Buy' ratings than a year ago. Several top-rated analysts have lowered price targets. Hedge fund activity in AAPL has also slowed. Insider confidence is muted. After years of being a consensus favorite, the stock is now drawing caution.
The problems run deeper than software bugs. Regulators have delayed Apple's AI rollout in China. CEO Tim Cook has been pulled into political crossfire as former President Donald Trump returns to the White House. New tariffs on China-made electronics have added pressure to Apple's supply chain. Cook has pledged $500 billion in U.S. investments, but most iPhone production still takes place overseas.
While Apple delays its AI rollout, the company's financial engine is quietly shifting. As shown below, gross profits from high-margin services have begun to rival hardware, underscoring why the stakes for Apple Intelligence are rising.
AI Roadmap Remains Unclear
At the same time, Apple's competitors have widened the AI gap. Microsoft is investing heavily in OpenAI and building custom data centers. Meta and Google are deploying their own foundation models across billions of users. Apple, in contrast, is now leaning on OpenAI to power parts of Siri. The company's privacy-first approach has also limited its ability to train cloud-scale models.
With WWDC set to begin, expectations are low. Investors are not looking for surprises. They want evidence that Apple can deliver what it has already promised. Whether that means releasing a functional Siri upgrade or showing meaningful progress elsewhere in its AI roadmap remains unclear.
In the meantime, AAPL still rests on a solid foundation. It has over 2 billion active devices and a growing services business. But the stock's premium valuation was built on the assumption of leadership. For now, the market is rethinking that assumption.
Is Apple Stock a Buy, Sell, or Hold?
Turning to Wall Street, Apple is considered a Moderate Buy, based on 29 analysts' ratings. The average price target for AAPL stock is $228.65, suggesting a 12.13% upside.
See more AAPL analyst ratings
Disclaimer & Disclosure Report an Issue
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
30 minutes ago
- Globe and Mail
Plug Power CFO Paul Middleton Underscores Continued Confidence in Strategic Growth with Additional Share Purchase
LATHAM, N.Y., June 09, 2025 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, today announced that Chief Financial Officer Paul Middleton has purchased an additional 650,000 shares of Plug's common stock on the open market. On June 9, 2025, Middleton acquired 650,000 shares at an average price of $1.0339 per share. This latest investment follows a previous purchase earlier this month, reinforcing Mr. Middleton's continued belief in Plug's long-term strategy, strong financial trajectory, and leadership in building a vertically integrated hydrogen ecosystem. 'This additional investment reflects my strong conviction in Plug's strategy and long-term value creation. As we execute and gain market traction, I continue to see meaningful upside and believe Plug remains one of the most compelling growth opportunities in the energy sector.' Middleton's open-market purchase underscores executive confidence in Plug's operational progress, including the ramp-up of hydrogen production plants, commercialization of GenEco electrolyzers, and growing demand for GenDrive fuel cell solutions across material handling and industrial markets. 'This is a transformative moment for our business and our industry. I believe deeply in Plug's ability to lead this energy transition—and I'm proud to continue investing in that future,' he added. The purchase was disclosed in a Form 4 filing with the U.S. Securities and Exchange Commission on June 9, 2025. About Plug Power Plug is building the global hydrogen economy with a fully integrated ecosystem spanning production, storage, delivery, and power generation. A first mover in the industry, Plug provides electrolyzers, liquid hydrogen, fuel cell systems, storage tanks, and fueling infrastructure to industries such as material handling, industrial applications, and energy producers—advancing energy independence and decarbonization at scale. With electrolyzers deployed across five continents, Plug leads in hydrogen production, delivering large-scale projects that redefine industrial power. The company has deployed over 72,000 fuel cell systems and 275 fueling stations and is the largest user of liquid hydrogen. Plug is rapidly expanding its generation network to ensure reliable, domestically produced supply, with hydrogen plants currently operational in Georgia, Tennessee, and Louisiana, capable of producing 39 tons per day. With employees and state-of-the-art manufacturing facilities across the globe, Plug powers global leaders like Walmart, Amazon, Home Depot, BMW, and BP. Safe Harbor This communication contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements about plans, goals, objectives, strategies, future events, expected results, beliefs, assumptions and any other statements that have not occurred. You are cautioned that such statements should not be read as a guarantee of future performance or results as such statements are subject to risks and uncertainties. Actual performance or results may differ materially from those expressed in these statements as a result of various factors, including, but not limited to, the following: the risk of elimination, nonrenewal, reduction of, or changes in qualifying criteria for government subsidies and economic incentives for alternative energy products, including the Inflation Reduction Act and its qualification to utilize the ITC; the anticipated benefits and actual savings and costs resulting from the implementation of cost-reduction measures; the risk that Plug's ability to achieve its business objectives and to continue to meet its obligations is dependent upon its ability to maintain a certain level of liquidity, which will depend in part on its ability to manage its cash flows; the risk that the funding of the Department of Energy loan may be delayed or cancelled; the risk that Plug may continue to incur losses and might never achieve or maintain profitability; the risk that Plug may not be successful in its financing initiatives and not have sufficient capital to continue its operations; the risk that Plug may not be able to expand its business or manage its future growth effectively; the risk that global economic uncertainty, including inflationary pressures, fluctuating interest rates, currency fluctuations, increase in tariffs, and supply chain disruptions, may adversely affect Plug's operating results; the risk that Plug may not be able to obtain from its hydrogen suppliers a sufficient supply of hydrogen at competitive prices or the risk that Plug may not be able to produce hydrogen internally at competitive prices; the risk that delays in or not completing its product and project development goals may adversely affect its revenue and profitability; the risk that its estimated future revenue may not be indicative of actual future revenue or profitability; the risk that volatility in commodity prices and product shortages may adversely affect Plug's gross margins and financial results; the risk that Plug may not be able to manufacture and market products on a profitable and large-scale commercial basis; and other risks relating to Plug's business that are described in Plug's public filings with the Securities and Exchange Commission, including the 'Risk Factors' section of Plug's Annual Report on Form 10-K for the year ended December 31, 2024, Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 as well as any subsequent filings. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made as of the date hereof and Plug disclaims any obligation to update forward-looking statements except as may be required by law. MEDIA CONTACT Teal Hoyos
Globe and Mail
44 minutes ago
- Globe and Mail
Is Fortinet's FortiGuard AI Service Becoming a Key Growth Driver?
Fortinet 's FTNT FortiGuard AI-powered security services have been gaining traction as more enterprises turn to real-time, automated protection to secure users, data and infrastructure. These services, which include threat intelligence, intrusion prevention, data loss prevention (DLP), antivirus and web filtering, are powered by FortiGuard Labs' global sensor network and AI models. Strong adoption has been driving top-line growth. In the first quarter of fiscal 2025, service revenues of $1.08 billion increased 14% year over year. Security subscriptions, including FortiGuard services, grew 16% year over year and remain a key driver of service growth. It made up 57.7% of Fortinet's service revenues in the first quarter. Services now make up more than 70% of Fortinet's total revenues, underscoring the importance of recurring, AI-powered solutions in its business model. Fortinet's continued focus on expanding FortiGuard's reach is visible in the launch of its AI-powered Workspace Security Suite. The suite protects key productivity platforms like Microsoft 365 and Google Workspace with AI-based phishing detection, impersonation defense, DLP and 24/7 incident response. These capabilities are fully backed by FortiGuard's intelligence and seamlessly integrate into Fortinet's broader Security Fabric to automate threat response and improve detection accuracy. Fortinet's AI services are a long-term growth driver. The company is deepening AI integration across its service portfolio and holds more than 500 AI-related patents. As demand grows for scalable, intelligence-led protection across hybrid and cloud environments, Fortinet expects its AI-enhanced services, such as FortiGuard, to contribute meaningfully to recurring, high-margin revenue growth. FTNT Faces Stiff Competition Fortinet's FortiGuard AI-powered services face growing competition from Palo Alto Networks PANW and Cisco Systems CSCO, both of which are expanding their AI security capabilities. Palo Alto Networks is expanding its AI security footprint with the acquisition of Protect AI, a leader in securing AI and ML applications. The move strengthens Palo Alto Networks' capabilities to defend against emerging threats like model manipulation and prompt injection. It reflects the company's push to lead in next-generation cybersecurity by addressing risks in the growing AI ecosystem. Meanwhile, Cisco Systems is boosting its AI security capabilities with updates to its XDR and Splunk platforms. It introduced agentic AI for faster threat detection and launched Foundation AI, featuring the first reasoning model for security. Cisco Systems also expanded its partnership with ServiceNow to support secure, scalable AI adoption. FTNT's Share Price Performance, Valuation and Estimates FTNT shares have risen 9.8% in the year-to-date (YTD) period, underperforming the Zacks Security industry's growth of 21.9%. FTNT has outperformed the Zacks Computer and Technology sector's return of 1.3%. FTNT's YTD Price Performance From a valuation standpoint, Fortinet stock is currently trading at a Price/Book ratio of 40.88X compared with the industry's 24.58X. FTNT has a Value Score of F. FTNT Valuation Image Source: Zacks Investment Research The Zacks Consensus Estimate for second-quarter 2025 earnings is pegged at 59 cents per share, unchanged over the past 30 days, indicating 3.51% year-over-year growth. The consensus mark for 2025 earnings is pegged at $2.48 per share, which has been revised upward by 2 cents over the past 30 days. The estimate indicates 4.64% year-over-year growth. Fortinet currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cisco Systems, Inc. (CSCO): Free Stock Analysis Report Fortinet, Inc. (FTNT): Free Stock Analysis Report Palo Alto Networks, Inc. (PANW): Free Stock Analysis Report
Globe and Mail
an hour ago
- Globe and Mail
Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space
Mergers and Acquisitions (M&A) have picked up significant pace in 2025 in the pharma/biotech sector after a passive run in 2024. The recent spree of acquisitions signifies a focus on portfolio expansion and constant pipeline innovation, given the changing landscape and spotlight on AI-driven drug discovery. Simultaneously, bigwigs in the space also enter into licensing deals and collaborations for a promising drug/candidate to strengthen and expand their portfolios in their respective core areas. Quick Take on Recent Acquisitions & Deals Pharma giant Sanofi SNY recently announced that it will acquire Blueprint Medicines for a total deal value of up to $9.5 billion to expand its portfolio in rare immunological disease and add an early-stage pipeline in immunology. The impending acquisition will add Blueprint Medicines' only marketed product, Ayvakit (avapritinib), an inhibitor of KIT and PDGFRA proteins, to Sanofi's commercial portfolio. Bristol Myers Squibb BMY recently announced a strategic collaboration agreement with BioNTech for the global co-development and co-commercialization of the latter's investigational bispecific antibody BNT327 across numerous solid tumor types. BNT327, a next-generation bispecific antibody candidate, targets PD-L1 and VEGF-A. Per the terms, BMY will make an upfront payment of $1.5 billion to BioNTech. In addition, BioNTech will also receive $2 billion in non-contingent anniversary payments through 2028. Developing bispecific antibodies that target two proteins, namely PD-1 and VEGF, has lately been one of the lucrative areas in cancer treatment, attracting other pharma giants as well. In May 2025, Pfizer inked a licensing agreement with 3SBio for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside China. While oncology and immuno-oncology companies have always been at the top of acquisition targets, the lucrative obesity sector and gene-editing space are also being eyed. Last week, Regeneron REGN entered into an in-licensing agreement for an obesity drug with Hansoh Pharmaceuticals Group Company Limited, in a bid to expand its clinical-stage obesity portfolio. The licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist. M&A in Focus in 2025 Consolidation has long been a central focus in the pharma/biotech industry. This is because leading companies constantly look to diversify their revenue base in the face of dwindling sales of their high-profile drugs. Acquisitions also make sense as developing a drug/technology from scratch is costly and risky. In April, pharma giant Johnson & Johnson acquired Intra-Cellular Therapies for approximately $14.6 billion and added antidepressant drug, Caplyta, to its neuroscience portfolio. Swiss pharma bigwig Novartis NVS, too, has been on an acquisition spree. Novartis is all set to acquire San Diego-based clinical-stage biopharmaceutical company Regulus Therapeutics to strengthen its renal disease portfolio. Regulus' lead asset, farabursen, is a potential first-in-class, next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. In April, Germany-based Merck KGaA announced that it will acquire SpringWorks Therapeutics, Inc. for $3.9 billion to expand business in the United States. SpringWorks Therapeutics, a U.S.-based biopharma company, has a portfolio that comprises a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas. Potential Deals We expect M&A activity to accelerate further in 2025, given the massive cash reserve owned by major pharma and biotech companies. These companies will also look to utilize innovative technology to develop breakthrough treatments rapidly as the landscape evolves. Moreover, smaller biotechs often lack the necessary funds to successfully develop a drug and commercialize thereafter. The recent spotlight on the usage of AI technology for drug discovery should lure investment in this industry. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report
